Sarepta Therapeutics Inc. plummeted after reporting a second patient died of acute liver failure while being treated with its gene therapy for a rare muscle disorder.

By Christy Santhosh and Bhanvi Satija (Reuters) -Shares of Sarepta Therapeutics slumped 42% on Monday after a second patient who had received its gene therapy, Elevidys, died in a span of three months ...

The FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

Yesterday, the New York Times reported that the FDA, in collaboration with USDA and other government agencies, plans to ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

Trump health officials signal eased FDA rules for rare disease gene therapy, but concerns linger over safety, oversight, and ...